Increased serum LOXL2 concentration in pelvic inflammatory disease with pelvic adhesion.
Lysyl oxidase-like 2
Pelvic adhesion
Pelvic inflammatory disease
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
05
03
2021
accepted:
25
02
2022
entrez:
5
3
2022
pubmed:
6
3
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Lysyl oxidase-like 2 (LOXL2) belongs to a family of the LOX secretory enzyme, which involves the cross-linkage of extracellular matrix (ECM) proteins. Here, we aimed to analyze the correlation between serum LOXL2 and pelvic adhesion in chronic pelvic inflammatory disease (PID). A total of 143 patients with PID and 130 healthy controls were included in this study. The serum levels of LOXL2 were measured using enzyme-linked immunosorbent assay (ELISA) kits. The patients were divided into non-adhesion group (102 cases) and adhesion group (41 cases). It was found that the serum level of LOXL2 expression was elevated in PID patients compared with healthy controls, and was elevated in PID patients with pelvic adhesion compared to patients without adhesion. In all PID patients, serum LOXL2 level was positively correlated with matrix metalloproteinases-9 (MMP-9), transforming growth factor-β (TGF-β1), whole blood viscosity (WBV) at low shear rate (LSR), WBV at high shear rate (HSR), and hematocrit (HcT). Multivariate logistic regression analysis showed that serum LOXL2 level was an independent risk factor for pelvic adhesion in PID patients (OR = 1.058; 95% CI = 1.030-1.086, P < 0.001). Serum LOXL2 level not only predicts the presence of PID, but serum LOXL2 concentration is also associated with the presence of pelvic adhesions.
Sections du résumé
BACKGROUND
Lysyl oxidase-like 2 (LOXL2) belongs to a family of the LOX secretory enzyme, which involves the cross-linkage of extracellular matrix (ECM) proteins. Here, we aimed to analyze the correlation between serum LOXL2 and pelvic adhesion in chronic pelvic inflammatory disease (PID).
METHODS
A total of 143 patients with PID and 130 healthy controls were included in this study. The serum levels of LOXL2 were measured using enzyme-linked immunosorbent assay (ELISA) kits. The patients were divided into non-adhesion group (102 cases) and adhesion group (41 cases).
RESULTS
It was found that the serum level of LOXL2 expression was elevated in PID patients compared with healthy controls, and was elevated in PID patients with pelvic adhesion compared to patients without adhesion. In all PID patients, serum LOXL2 level was positively correlated with matrix metalloproteinases-9 (MMP-9), transforming growth factor-β (TGF-β1), whole blood viscosity (WBV) at low shear rate (LSR), WBV at high shear rate (HSR), and hematocrit (HcT). Multivariate logistic regression analysis showed that serum LOXL2 level was an independent risk factor for pelvic adhesion in PID patients (OR = 1.058; 95% CI = 1.030-1.086, P < 0.001).
CONCLUSIONS
Serum LOXL2 level not only predicts the presence of PID, but serum LOXL2 concentration is also associated with the presence of pelvic adhesions.
Identifiants
pubmed: 35246120
doi: 10.1186/s12905-022-01640-1
pii: 10.1186/s12905-022-01640-1
pmc: PMC8896148
doi:
Substances chimiques
Amino Acid Oxidoreductases
EC 1.4.-
LOXL2 protein, human
EC 1.4.3.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
59Informations de copyright
© 2022. The Author(s).
Références
Cochrane Database Syst Rev. 2014 Jul 09;(7):CD001298
pubmed: 25005450
Med Sci Monit. 2019 Nov 30;25:9094-9102
pubmed: 31784502
Biosci Rep. 2017 Nov 21;37(6):
pubmed: 29089463
Biosci Rep. 2016 Jul 15;36(4):
pubmed: 27247426
Eur Respir J. 2014 May;43(5):1430-8
pubmed: 24177001
Med Princ Pract. 2018;27(2):173-178
pubmed: 29421801
Phytother Res. 2012 Jul;26(7):1037-47
pubmed: 22183741
Kidney Int. 2018 Aug;94(2):303-314
pubmed: 29759420
Oncogenesis. 2019 May 13;8(5):34
pubmed: 31086173
Am J Pathol. 2020 Jan;190(1):145-157
pubmed: 31610174
MMWR Recomm Rep. 2010 Dec 17;59(RR-12):1-110
pubmed: 21160459
J Drug Target. 2019 Aug;27(7):790-796
pubmed: 30457362
Fertil Steril. 2019 May;111(5):1002-1010.e2
pubmed: 30922643
Fertil Steril. 2019 Sep;112(3):417-425
pubmed: 31446901
Clinics (Sao Paulo). 2018 Aug 09;73:e364
pubmed: 30110069
Biofactors. 2019 Nov;45(6):959-974
pubmed: 31336025
Am Fam Physician. 2019 Sep 15;100(6):357-364
pubmed: 31524362
Arch Gynecol Obstet. 2016 May;293(5):941-9
pubmed: 26739265
J Obstet Gynaecol. 2017 Feb;37(2):228-232
pubmed: 27750467
Clin Rheumatol. 2018 Jan;37(1):193-198
pubmed: 29052023
Medicine (Baltimore). 2018 Aug;97(31):e11760
pubmed: 30075598
Facts Views Vis Obgyn. 2019 Jun;11(2):137-149
pubmed: 31824635
J Clin Med. 2018 Oct 24;7(11):
pubmed: 30352985
Int J Mol Sci. 2019 Nov 10;20(22):
pubmed: 31717614
Reprod Sci. 2015 Dec;22(12):1496-508
pubmed: 25963914
Reprod Sci. 2018 Jul;25(7):978-979
pubmed: 28100109
Bioorg Chem. 2014 Dec;57:231-241
pubmed: 25146937
Int J Mol Med. 2018 Dec;42(6):3530-3541
pubmed: 30320382
Essays Biochem. 2019 Sep 13;63(3):349-364
pubmed: 31488698
Arch Gynecol Obstet. 2019 Dec;300(6):1507-1520
pubmed: 31729562
Fertil Steril. 2009 Nov;92(5):1679-84
pubmed: 18937938
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986934
J Ethnopharmacol. 2017 Aug 17;208:57-65
pubmed: 28652014
Dis Model Mech. 2017 Nov 1;10(11):1301-1312
pubmed: 29125826
Clin Exp Reprod Med. 2020 Jun;47(2):108-113
pubmed: 32460455